Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer

NCT00320359 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

700

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer, Small Cell

Interventions

DRUG: Intravenous topotecan/cisplatin
DRUG: Intravenous etoposide/cisplatin

Sponsor

GlaxoSmithKline